Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Operating Expenses for 8 consecutive years, with $103.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Expenses rose 11.77% year-over-year to $103.2 million; the TTM figure through May 2026 stood at $397.9 million (up 24.81% YoY), while the FY2025 annual figure was $369.6 million, up 38.15% from the prior year.
• Operating Expenses climbed to $103.2 million in Q2 2026 per NRIX's latest filing, from $98.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $103.2 million in Q2 2026 and bottomed at $52.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $71.9 million across 5 years, with a median of $61.2 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 77.31% — and 2023, when it grew 0.51%.
• Nurix Therapeutics' Operating Expenses stood at $55.5 million in 2022, then climbed by 9.05% to $60.5 million in 2023, then advanced by 28.84% to $77.9 million in 2024, then grew by 24.03% to $96.7 million in 2025, then rose by 6.8% to $103.2 million in 2026.
• Business Quant data shows NRIX's Operating Expenses at $103.2 million in Q2 2026, $98.7 million in Q1 2026, and $96.7 million in Q4 2025.